| Name | Title | Contact Details |
|---|
Blue Cross Blue Shield of Michigan is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Detroit, MI. To find more information about Blue Cross Blue Shield of Michigan, please visit www.bcbsm.com
PHS is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Universal-Macomb Ambulance is a Sterling Heights, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Agility Health is a leading healthcare provider devoted to the rehabilitation of our patients' physical injuries and conditions. Established in 1968, Agility Health delivers personalized care through over one million therapy visits annually at more than 155 service sites in 20 states nationwide. Our team is dedicated to providing exceptional value to the patients, clients and partners we serve. Through our innovative clinical services, proven practice management systems and flexible partnerships, we help achieve optimal performance in a variety of settings, including outpatient clinics, hospitals, long-term care facilities and employer work sites. Agility Health is one of the top 10 rehabilitation services companies in the United States, with a strategic vision to become a leading national source for rehabilitation.
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.